27 November 2018 | News
iGenetic will be distributing Lucence’s flagship liquid biopsy test – LiquidHALLMARK, the world’s first blood test to span multiple cancer-causing mutations and viruses.
Singapore – Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, and iGenetic Diagnostics, a leading pathology company with operations across India, have announced a partnership to distribute Lucence’s liquid biopsy tests for early cancer detection and treatment in India.
iGenetic will be distributing Lucence’s flagship liquid biopsy test – LiquidHALLMARK, the world’s first blood test to span multiple cancer-causing mutations and viruses. This test improves cancer diagnosis and treatment selection for patients with advanced cancer. The blood test analyzes the cancer-driving mutations from the DNA shed by the tumor into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy.
LiquidHALLMARK targets a wide range of cancers, especially the cancer types that are most prevalent in Asia, like lung, colon and breast cancers. The turnaround time for this test is also shorter with results coming back in days instead of over a week for current approaches. The test is based on Lucence’s proprietary molecular watermarking technology AmpliMARK with sensitivity and specificity of up to 99.9%, which is supported by its AI-powered clinical analytics engine SunTzu.AI.
iGenetic specialises in providing the full spectrum of pathology solutions including molecular diagnostic services that deliver quicker and accurate results for its customers. The company is headquartered in Mumbai with seven processing labs and over 20 collection centres across India.
“Delivering advanced molecular diagnostics that can enable a quick and precise diagnosis will help to save lives. We are excited to collaborate with Lucence to deliver their proprietary liquid biopsy tests for early cancer detection and better treatment selection to patients in India. Lucence’s technology will help doctors personalize treatment for their patients and improve patient outcomes,’’ said Arunima Patel, CEO, iGenetic Diagnostics.
“Lucence is delighted to collaborate with iGenetic to launch our liquid biopsy tests in India. We are focused on reducing avoidable cancer deaths, particularly in Asia, where more than 4 million cancer deaths occur annually. With iGenetic’s experience and presence in India, we are confident that this partnership will drive better cancer care in India’’, said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.